Endpoints NewsOriginal article
Roche kidney drug's Phase 3 win sets up path to accelerated approval
Phase 3positivePositive
AI Analysis
Summary
Roche reported positive interim Phase 3 results for its kidney disease drug, positioning the company for potential accelerated approval in a market already occupied by several competitors including Novartis, Calliditas, Travere, Otsuka, and Vera.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
interim Phase 3 results reported
Importance:7/10
Sentiment:
0.70
Phase 3kidney diseaseaccelerated approvalpositive data
Related Companies
Read the original article
Published by Endpoints News on September 23, 2026 10:18 AM